Keywords: Afatinib; Rash; Minocycline; Tetracycline; Epidermal growth factor inhibitor;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: EGFR tyrosine kinase inhibitor; Gefitinib; Osimertinib; Afatinib;
Keywords: Acute pneumonitis; Afatinib; Anti PD-1 antibody; Immune checkpoint inhibitor; EGFR-TKI; epidermal growth factor receptor-tyrosine kinase inhibitor; PD-1; programmed cell death-1; PD-L1; programmed cell death ligand-1; NSCLC; non-small cell lung cancer; BA
Keywords: Afatinib; Erlotinib; Gefitinib; Mutation; NSCLC;
Keywords: Non-small cell lung cancer; Epidermal growth factor receptor (EGFR); Tyrosine kinase inhibitors (TKI); TKI resistance; Osimertinib; Gefitinib; Erlotinib; Afatinib;
Keywords: Afatinib; Colorectal cancer; EGFR; Combination therapy; AE; adverse events; CLX; cell line xenograft; CR; complete response; (m)CRC; (metastatic) colorectal cancer; EGFR; epidermal growth factor receptor; GI; gastrointestinal; HNSCC; head and neck squamou
Keywords: Non-small cell lung cancer; EGFR mutation; Afatinib; Acquired resistance; T790M; Progression biopsy;
Keywords: Afatinib; Non-small cell lung cancer; Tetracycline; Skin toxicities; Toxicity severity; Tirosine kinase inhibitors;
Keywords: Afatinib; Non-small cell lung cancer; EGFR;
Keywords: Afatinib; Chemotherapy; Dacomitinib; Epidermal growth factor receptor; Erlotinib; Gefitinib; Non-small cell lung cancer; Pharmacokinetics; Tyrosine kinase inhibitors;
Keywords: Meta-analysis; Lung cancer; Gefitinib; Afatinib; Erlotinib; Ethnicity; Trial design;
Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib
Keywords: EGFR; L718V; Osimertinib; Afatinib; Resistance; NSCLC;
Melanoma-associated antigen A11 reduces erlotinib and afatinib efficacy in head and neck cancer
Keywords: MAGE-A11; Melanoma-associated antigens; Head and neck cancer; Erlotinib; Afatinib;
Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea
Keywords: Afatinib; Epidermal growth factor receptor; Compassionate use pragram; Non-small cell lung cancer;
A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404
Keywords: Non-small-cell lung cancer; EGFR; Bevacizumab; Afatinib; EGFR-TKI; Phase Ib;
Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC
Keywords: EGFR exon 20 insertion; Afatinib; Cetuximab; NSCLC;
A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours
Keywords: Afatinib; ErbB family blocker; Cetuximab; Solid tumours; Phase 1b;
EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer
Keywords: Afatinib; EGFR; ILF3; Lung cancer; YM155;
Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC
Keywords: Osimertinib; Afatinib; EGFR triple mutation; P794L mutation NSCLC;
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door
Keywords: Personalised medicine; Targeted therapy; ERBB3; Tyrosine kinase inhibitors; Trastuzumab; Afatinib; Lapatinib;
A novel pH-sensitive liposome to trigger delivery of afatinib to cancer cells: Impact on lung cancer therapy
Keywords: Afatinib; pH-sensitive liposomes; In vitro release; Anticancer activity; Lung cancers;
Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer
Keywords: Breast cancer; Central nervous system (CNS) metastases; HER2; Small-molecule tyrosine kinase inhibitors; Lapatinib; Neratinib; Afatinib; Tucatinib;
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma
Keywords: Afatinib; Driver; HER2 mutation; Poziotinib; Targeted therapy;
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung canc
Keywords: AFAT; afatinib; ALK; anaplastic lymphoma kinase; CRIZ; crizotinib; CS; calibration standard; CV; coefficient of variation; DMSO; dimethylsulfoxide; EGFR; epidermal growth factor receptor; ERLO; erlotinib; IQC; internal quality control; IS; internal standa
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients
Keywords: Afatinib; Depth of response; EGFR mutation-positive NSCLC; Gefitinib;
An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach
Keywords: Afatinib; Del19; Gefitinib; L858R; T790M;
Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer
Keywords: Afatinib; Epidermal growth factor receptor; ErbB receptors; Non-small cell lung cancer; Tyrosine kinase inhibitor;
Endocannabinoid Signaling in Embryonic Neuronal Motility and Cell-Cell Contact - Role of mGluR5 and TRPC3 Channels
Keywords: 2-AG; 2-arachidonoyl glycerol; [Ca2+]i; intracellular free calcium concentration; Afatinib; N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide; AM251; 1-(2,4-dichlorophenyl)-5-(4-iodophe
Original articleA phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib
Keywords: AE; adverse events; Afa; afatinib; AR; acquired resistance; AUC; area under curve; CR; complete response; CTCAE; Common Terminology Criteria for Adverse Events; CTP; clinical trial protocol; DLT; dose-limiting toxicity; ECOG; Eastern Cooperative Oncology
Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer
Keywords: MicroRNA; miR-34a; Erlotinib; Afatinib; Osimertinib; Rociletinib; EGFR:; epidermal growth factor receptor; TKI:; tyrosine kinase inhibitor; miRNA:; microRNA; DRI:; dose reduction index; CI:; combination index; NSCLC:; non-small cell lung cancer;
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib
Keywords: Phase Ib; Afatinib; Cetuximab; NSCLC; EGFR;
Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation
Keywords: Afatinib; Tyrosine kinase inhibitor; ABCB1; ABCG2; Brain accumulation; Oral availability;
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going
Keywords: NSCLC; EGFR mutations; Osimertinib; Olmutinib; Rociletinib; Afatinib; EGFR TKI; Resistance;
EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib
Keywords: NSCLC; EGFR mutation; Afatinib; Targeted therapy;
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies
Keywords: ERBB2; HER2; Targeted therapy; Afatinib; Trastuzumab;
Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials
Keywords: Afatinib; Dacomitinib; Erlotinib; Gefitinib; Icotinib;
HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib
Keywords: NSCLC; HER2 V659; HER2 G660; Transmembrane mutation; Afatinib; Actionable driver mutation;
Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient
Keywords: SJS; NSCLC; TKI; Afatinib;
Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation
Keywords: EGFR mutation; KRAS mutation; Afatinib; Non-small cell lung cancer; Tyrosine kinase inhibitor;
Metástasis coroidea como signo de presentación de un adenocarcinoma de pulmón con respuesta a afatinib
Keywords: Metástasis coroidea; Adenocarcinoma de pulmón; Tumores coroideos; Afatinib; Mutación EFGR; Choroidal metastasis; Lung adenocarcinoma; Choroidal tumours; Afatinib; EFGR mutation;
Afatinib en pacientes con carcinoma escamoso de pulmón: contexto actual y opción de un tratamiento oral
Keywords: Cáncer de pulmón; Cáncer epidermoide; Cáncer avanzado; Segunda línea; Afatinib; ErbB; Erlotinib; QuimioterapiaLung cancer; Epidermoid; Advanced; Second line; Afatinib; ErbB; Erlotinib; Chemotherapy
Mecanismo de acción y desarrollo preclínico de afatinib
Keywords: Afatinib; Gefitinib; Erlotinib; Cáncer de pulmón de célula no pequeña; avanzado; Receptor del factor de crecimiento epidérmico; Familia ErbBAfatinib; Gefitinib; Erlotinib; Advanced non-small cell lung cancer; Epidermal growth factor receptor; ErbB family
Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas
Keywords: Lung cancer; Adenocarcinoma; ERBB2; HER2; Exon 20; Afatinib;
A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma
Keywords: Afatinib; Carboplatin; Paclitaxel; Head and neck squamous cell carcinoma; Efficacy; Toxicity; ABCB1; Phase I trial;
Evidencia de afatinib en pacientes que progresan a un tratamiento de primera lÃnea
Keywords: Afatinib; EGFR; Segunda lÃnea; Afatinib; EGFR; Second-line;
Tratamiento con afatinib en primera línea EGFR M+. Resultados según subtipo de mutación
Keywords: EGFR; Cáncer de pulmón; Inhibidores de la tirosincinasa; Afatinib; Mutaciones activadoras; Mutaciones no comunesEGFR; Lung cancer; Tyrosine kinase inhibitors; Afatinib; Activating mutations; Uncommon mutations
Liquid chromatographyâ¿¿tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the Oâ¿¿desmethyl metabolites of erlotinib and gefitinib in human plasma
Keywords: EGFR; epidermal growth factor receptor; IS; internal standard; LCâ¿¿MS/MS; liquid chromatographyâ¿¿tandem mass spectrometry; LLOQ; lower limit of quantification; SRM; selected reaction monitoring; QC; quality control; Afatinib; Erlotinib; Gefitinib; Encor
Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors
Keywords: Afatinib; NSCLC; Clinical trials; EGFR; Head-neck
Design, synthesis, and docking studies of afatinib analogs bearing cinnamamide moiety as potent EGFR inhibitors
Keywords: Afatinib; Cinnamamide; Synthesis; Docking; EGFR inhibitors; Antitumor activity
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases
Keywords: Afatinib; NSCLC; Brain metastases; Epidermal growth factor receptor;